RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Amid the coronavirus pandemic, President Trump said he’ll soon sign an executive order on deregulation.
He also said, during a televised portion of a Cabinet meeting, that the U.S. is ahead of schedule on developing virus therapeutics and vaccines.
CytoDyn (OTCQB:CYDY) will be coordinating with the National Institutes of Health (NIH) of Mexico and providing leronlimab for a trial for the severe/critical COVID-19 population in Mexico, with the potential to collaborate on further CytoDyn COVID-19 trials.
The study is anticipated to consist of ~30 patients with potential involvement of the NIH of Mexico in other CytoDyn trials.
CytoDyn is currently enrolling a Phase 2b/3 clinical trial for 390 patients and Phase 2 trial with 75 patients in the mild-to-moderate COVID-19 population.
Roche (OTCQX:RHHBY) announces that its Elecsys Anti-SARS-CoV-2 antibody blood test is “live” at more than 20 U.S. commercial and hospital laboratories.
More than 200 sites will be up and running in the next few weeks with the collective ability to perform “millions” of tests in a seven-day period.
Citing declining sales in response to ongoing lawsuits over claimed asbestos exposure, Johnson & Johnson (NYSE:JNJ) has decided to stop selling its talc-based Baby Powder in the U.S. and Canada. Sales will continue elsewhere.
Under Priority Review status, the FDA accepts Eiger BioPharmaceuticals’ (NASDAQ:EIGR) marketing application seeking approval of Zokinvy (lonafarnib) for the treatment of progeria and progeroid laminopathies, a rare inherited disorder characterized by rapid aging (most children do not live past their early teens).
The agency’s action date is November 20. No advisory committee meeting is planned.
Shares up 2% after hours.
